TPCW
CODX

TD Private Client Wealth’s Co-Diagnostics CODX Stock Holding History

TD Private Client Wealth’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1
Closed -$334 – 1222
2021
Q1 		$334 Buy
+1
New +$399 ﹤0.01% 1154

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ARC
Advisor Resource Council Dallas, Texas $309M AUM 22.32% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

TD Private Client Wealth's CODX Position: Q2 2021 in Review

TD Private Client Wealth sold out of Co-Diagnostics (CODX) in Q2 2021, closing a stake of 1 share — an estimated $334 sold.

TD Private Client Wealth first reported a position in CODX in Q1 2021 and held it in 1 quarter. The position peaked at $334 in Q1 2021. 88 funds tracked by Wall St. Rank hold CODX as of Q2 2021.

  • TD Private Client Wealth reported no remaining Co-Diagnostics position as of Q2 2021 after selling out during the quarter.
  • TD Private Client Wealth sold 1 Co-Diagnostics share in Q2 2021, an estimated $334.
  • TD Private Client Wealth first reported a position in Co-Diagnostics in Q1 2021 and held it in 1 quarter.
  • TD Private Client Wealth's Co-Diagnostics position peaked at $334 in Q1 2021.
  • 88 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2021.

Based on TD Private Client Wealth's 13F filing for Q2 2021, filed 16 Aug 2024.